Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Enterprise Value (2016 - 2026)

Intellia Therapeutics has reported Enterprise Value over the past 12 years, most recently at -$376.0 million for Q1 2026.

  • Quarterly Enterprise Value rose 25.36% to -$376.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$376.0 million through Mar 2026, up 25.36% year-over-year, with the annual reading at -$449.9 million for FY2025, 25.21% up from the prior year.
  • Enterprise Value was -$376.0 million for Q1 2026 at Intellia Therapeutics, up from -$449.9 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$376.0 million in Q1 2026 and troughed at -$1.2 billion in Q4 2022.
  • The 5-year median for Enterprise Value is -$791.3 million (2024), against an average of -$729.5 million.
  • Year-over-year, Enterprise Value crashed 65.26% in 2022 and then skyrocketed 36.34% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$1.2 billion in 2022, then increased by 23.51% to -$912.2 million in 2023, then surged by 34.06% to -$601.5 million in 2024, then rose by 25.21% to -$449.9 million in 2025, then grew by 16.43% to -$376.0 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Enterprise Value are -$376.0 million (Q1 2026), -$449.9 million (Q4 2025), and -$511.0 million (Q3 2025).